Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »
Avidity begins Cohort C enrollment in FORTITUDE trial
Fulcrum halts losmapimod development
Fulcrum halts losmapimod development by June Kinoshita This morning, we received news Fulcrum has decided to halt its development of losmapimod (see press release below). Fulcrum’s decision was based on… Read More »
A note to our families from CEO Mark Stone
A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore,… Read More »
Advocating for Change on Capitol Hill
A Day of Impact in Washington, D.C. On May 8th, the FSHD Society held its first-ever Day on Capitol Hill in Washington, D.C. This milestone in our advocacy efforts brought… Read More »
FSHD Representation in Film Fest Favorite ‘Good Bad Things’
Good Bad Things breaks barriers and earns accolades by Erin Saxon, FSHD Society In August, we shared exciting news about Good Bad Things, a film that promised to challenge perceptions… Read More »